Annual SG&A
$7.12 M
-$2.74 M-27.77%
31 December 2023
Summary:
Theriva Biologics annual selling, general & administrative expenses is currently $7.12 million, with the most recent change of -$2.74 million (-27.77%) on 31 December 2023. During the last 3 years, it has risen by +$2.09 million (+41.58%). TOVX annual SG&A is now -29.80% below its all-time high of $10.14 million, reached on 01 December 2016.TOVX Selling, General & Administrative Expenses Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly SG&A
$2.30 M
+$835.00 K+56.92%
01 September 2024
Summary:
Theriva Biologics quarterly selling, general & administrative expenses is currently $2.30 million, with the most recent change of +$835.00 thousand (+56.92%) on 01 September 2024. Over the past year, it has increased by +$2.09 million (+985.85%). TOVX quarterly SG&A is now -49.26% below its all-time high of $4.54 million, reached on 01 March 2001.TOVX Quarterly SG&A Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM SG&A
-$1.28 B
-$26.69 M-2.13%
01 September 2024
Summary:
Theriva Biologics TTM selling, general & administrative expenses is currently -$1.28 billion, with the most recent change of -$26.69 million (-2.13%) on 01 September 2024. Over the past year, it has dropped by -$1.29 billion (-13764.94%). TOVX TTM SG&A is now -6229778.05% below its all-time high of $11.55 million, reached on 30 June 2023.TOVX TTM SG&A Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TOVX Selling, General & Administrative Expenses Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -27.8% | +985.9% | -10000.0% |
| 3 y3 years | +41.6% | -7.4% | -10000.0% |
| 5 y5 years | +55.5% | +79.4% | -10000.0% |
TOVX Selling, General & Administrative Expenses High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -27.8% | +41.6% | -45.8% | +985.9% | -20.5% | at low |
| 5 y | 5 years | -27.8% | +55.5% | -45.8% | +985.9% | -39.0% | at low |
| alltime | all time | -29.8% | +2392.1% | -49.3% | +675.5% | <-9999.0% | at low |
Theriva Biologics Selling, General & Administrative Expenses History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | $2.30 M(+56.9%) | $7.72 M(+37.1%) |
| June 2024 | - | $1.47 M(-24.1%) | $5.63 M(-17.8%) |
| Mar 2024 | - | $1.93 M(-4.4%) | $6.85 M(-3.8%) |
| Dec 2023 | $7.12 M(-27.8%) | $2.02 M(+853.3%) | $7.12 M(-23.8%) |
| Sept 2023 | - | $212.00 K(-92.1%) | $9.35 M(-19.1%) |
| June 2023 | - | $2.69 M(+22.1%) | $11.55 M(+11.0%) |
| Mar 2023 | - | $2.20 M(-48.2%) | $10.40 M(+5.5%) |
| Dec 2022 | $9.86 M(+52.3%) | $4.25 M(+75.7%) | $9.86 M(+21.7%) |
| Sept 2022 | - | $2.42 M(+56.8%) | $8.10 M(+15.9%) |
| June 2022 | - | $1.54 M(-6.9%) | $6.99 M(+4.1%) |
| Mar 2022 | - | $1.66 M(-33.4%) | $6.71 M(+3.6%) |
| Dec 2021 | $6.47 M(+28.7%) | - | - |
| Dec 2021 | - | $2.49 M(+90.8%) | $6.47 M(+25.9%) |
| Sept 2021 | - | $1.30 M(+3.0%) | $5.14 M(+2.1%) |
| June 2021 | - | $1.26 M(-10.9%) | $5.03 M(-0.4%) |
| Mar 2021 | - | $1.42 M(+23.1%) | $5.05 M(+0.5%) |
| Dec 2020 | $5.03 M(+9.8%) | $1.15 M(-3.7%) | $5.03 M(-2.5%) |
| Sept 2020 | - | $1.20 M(-6.9%) | $5.16 M(+2.0%) |
| June 2020 | - | $1.29 M(-7.7%) | $5.06 M(+5.0%) |
| Mar 2020 | - | $1.39 M(+8.6%) | $4.82 M(+5.2%) |
| Dec 2019 | $4.58 M(-20.0%) | $1.28 M(+16.8%) | $4.58 M(+1.8%) |
| Sept 2019 | - | $1.10 M(+5.2%) | $4.50 M(-7.7%) |
| June 2019 | - | $1.04 M(-9.5%) | $4.87 M(-7.4%) |
| Mar 2019 | - | $1.15 M(-4.0%) | $5.26 M(-8.1%) |
| Dec 2018 | $5.73 M(-23.3%) | $1.20 M(-18.5%) | $5.73 M(-12.6%) |
| Sept 2018 | - | $1.47 M(+3.0%) | $6.55 M(-3.4%) |
| June 2018 | - | $1.43 M(-11.7%) | $6.78 M(-3.0%) |
| Mar 2018 | - | $1.62 M(-20.1%) | $7.00 M(-6.3%) |
| Dec 2017 | $7.47 M(-26.4%) | $2.03 M(+18.9%) | $7.47 M(-16.2%) |
| Sept 2017 | - | $1.71 M(+3.7%) | $8.91 M(-4.2%) |
| June 2017 | - | $1.64 M(-21.3%) | $9.30 M(-5.1%) |
| Mar 2017 | - | $2.09 M(-39.9%) | $9.81 M(-3.3%) |
| Dec 2016 | $10.14 M(+25.6%) | $3.48 M(+65.9%) | $10.14 M(+10.2%) |
| Sept 2016 | - | $2.10 M(-2.4%) | $9.20 M(+5.6%) |
| June 2016 | - | $2.15 M(-11.5%) | $8.71 M(-0.9%) |
| Mar 2016 | - | $2.43 M(-4.3%) | $8.79 M(+8.8%) |
| Dec 2015 | $8.07 M(+34.3%) | $2.54 M(+58.0%) | $8.07 M(+9.1%) |
| Sept 2015 | - | $1.60 M(-27.8%) | $7.40 M(+5.5%) |
| June 2015 | - | $2.22 M(+29.7%) | $7.01 M(+6.2%) |
| Mar 2015 | - | $1.71 M(-7.9%) | $6.60 M(+9.8%) |
| Dec 2014 | $6.01 M(+3.1%) | $1.86 M(+52.6%) | $6.01 M(+5.2%) |
| Sept 2014 | - | $1.22 M(-32.9%) | $5.72 M(-10.5%) |
| June 2014 | - | $1.81 M(+61.7%) | $6.39 M(+9.5%) |
| Mar 2014 | - | $1.12 M(-28.2%) | $5.83 M(0.0%) |
| Dec 2013 | $5.83 M(+16.4%) | $1.56 M(-17.4%) | $5.83 M(+4.8%) |
| Sept 2013 | - | $1.89 M(+50.2%) | $5.57 M(+17.2%) |
| June 2013 | - | $1.26 M(+12.1%) | $4.75 M(+1.8%) |
| Mar 2013 | - | $1.12 M(-13.4%) | $4.67 M(-6.9%) |
| Dec 2012 | $5.01 M(+93.7%) | $1.29 M(+20.7%) | $5.01 M(+26.4%) |
| Sept 2012 | - | $1.07 M(-8.8%) | $3.97 M(+14.1%) |
| June 2012 | - | $1.18 M(-19.9%) | $3.48 M(+23.1%) |
| Mar 2012 | - | $1.47 M(+489.6%) | $2.82 M(+9.1%) |
| Dec 2011 | $2.59 M(+22.2%) | $249.00 K(-57.2%) | $2.59 M(+5.4%) |
| Sept 2011 | - | $582.00 K(+11.1%) | $2.46 M(-0.8%) |
| June 2011 | - | $524.00 K(-57.5%) | $2.48 M(-5.3%) |
| Mar 2011 | - | $1.23 M(+956.6%) | $2.61 M(+23.1%) |
| Dec 2010 | $2.12 M | $116.70 K(-80.6%) | $2.12 M(-34.9%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2010 | - | $601.80 K(-9.2%) | $3.26 M(+8.3%) |
| June 2010 | - | $662.60 K(-10.7%) | $3.01 M(+6.7%) |
| Mar 2010 | - | $742.00 K(-40.9%) | $2.82 M(+5.6%) |
| Dec 2009 | $2.71 M(+1.2%) | $1.26 M(+257.3%) | $2.68 M(+44.5%) |
| Sept 2009 | - | $351.60 K(-25.8%) | $1.85 M(-12.1%) |
| June 2009 | - | $474.00 K(-20.1%) | $2.11 M(-7.0%) |
| Mar 2009 | - | $593.40 K(+37.1%) | $2.27 M(-15.3%) |
| Dec 2008 | $2.68 M(-29.8%) | $432.80 K(-28.7%) | $2.68 M(-16.4%) |
| Sept 2008 | - | $606.70 K(-4.2%) | $3.20 M(+0.2%) |
| June 2008 | - | $633.60 K(-36.8%) | $3.19 M(-3.5%) |
| Mar 2008 | - | $1.00 M(+4.6%) | $3.31 M(-13.2%) |
| Dec 2007 | $3.81 M(+164.8%) | $958.50 K(+59.9%) | $3.81 M(+6.5%) |
| Sept 2007 | - | $599.40 K(-20.0%) | $3.58 M(+12.0%) |
| June 2007 | - | $748.90 K(-50.2%) | $3.20 M(+15.9%) |
| Mar 2007 | - | $1.50 M(+106.7%) | $2.76 M(+91.7%) |
| Dec 2006 | $1.44 M(+403.7%) | $727.50 K(+236.6%) | $1.44 M(+102.2%) |
| Sept 2006 | - | $216.10 K(-30.6%) | $711.50 K(+43.6%) |
| June 2006 | - | $311.20 K(+68.9%) | $495.40 K(+168.9%) |
| Mar 2006 | - | $184.20 K(-53.8%) | $184.20 K(-93.7%) |
| Dec 2005 | $285.70 K(-93.6%) | - | - |
| Mar 2003 | - | $398.80 K(-19.1%) | $2.94 M(-34.4%) |
| Dec 2002 | $4.48 M(-1.5%) | $493.00 K(-18.9%) | $4.48 M(-20.4%) |
| Sept 2002 | - | $607.80 K(-57.9%) | $5.63 M(-7.0%) |
| June 2002 | - | $1.44 M(-25.6%) | $6.06 M(+5.6%) |
| Mar 2002 | - | $1.94 M(+18.0%) | $5.73 M(-31.2%) |
| Dec 2001 | $4.55 M(+61.6%) | $1.64 M(+59.2%) | $8.33 M(+9.6%) |
| Sept 2001 | - | $1.03 M(-7.9%) | $7.60 M(+7.2%) |
| June 2001 | - | $1.12 M(-75.3%) | $7.09 M(+6.4%) |
| Mar 2001 | - | $4.54 M(+398.4%) | $6.66 M(+136.4%) |
| Dec 2000 | $2.82 M(+23.7%) | $910.30 K(+74.7%) | $2.82 M(+9.0%) |
| Sept 2000 | - | $521.10 K(-24.6%) | $2.58 M(+0.8%) |
| June 2000 | - | $691.40 K(-0.5%) | $2.56 M(+3.7%) |
| Mar 2000 | - | $694.70 K(+2.6%) | $2.47 M(+8.6%) |
| Dec 1999 | $2.28 M(-24.1%) | $677.10 K(+35.4%) | $2.28 M(+8.4%) |
| Sept 1999 | - | $500.00 K(-16.7%) | $2.10 M(-19.2%) |
| June 1999 | - | $600.00 K(+20.1%) | $2.60 M(-10.3%) |
| Mar 1999 | - | $499.70 K(-0.1%) | $2.90 M(-3.3%) |
| Dec 1998 | $3.00 M(-34.8%) | $500.00 K(-50.0%) | $3.00 M(-25.0%) |
| Sept 1998 | - | $1.00 M(+11.1%) | $4.00 M(-7.0%) |
| June 1998 | - | $900.00 K(+50.0%) | $4.30 M(-2.3%) |
| Mar 1998 | - | $600.00 K(-60.0%) | $4.40 M(-4.3%) |
| Dec 1997 | $4.60 M(-40.3%) | $1.50 M(+15.4%) | $4.60 M(-13.2%) |
| Sept 1997 | - | $1.30 M(+30.0%) | $5.30 M(-13.1%) |
| June 1997 | - | $1.00 M(+25.0%) | $6.10 M(+3.4%) |
| Mar 1997 | - | $800.00 K(-63.6%) | $5.90 M(+7.3%) |
| Dec 1996 | $7.70 M(+156.7%) | $2.20 M(+4.8%) | $5.50 M(+89.7%) |
| Sept 1996 | - | $2.10 M(+162.5%) | $2.90 M(+81.3%) |
| June 1996 | - | $800.00 K(+100.0%) | $1.60 M(+100.0%) |
| Mar 1996 | - | $400.00 K(-200.0%) | $800.00 K(+100.0%) |
| Dec 1995 | $3.00 M(-53.1%) | -$400.00 K(-150.0%) | $400.00 K(-50.0%) |
| Sept 1995 | - | $800.00 K(+166.7%) | $800.00 K(-76.5%) |
| Dec 1994 | $6.40 M(+77.8%) | - | - |
| Mar 1994 | - | $300.00 K(-72.7%) | $3.40 M(-2.9%) |
| Dec 1993 | $3.60 M | $1.10 M(-26.7%) | $3.50 M(+45.8%) |
| Sept 1993 | - | $1.50 M(+200.0%) | $2.40 M(+166.7%) |
| June 1993 | - | $500.00 K(+25.0%) | $900.00 K(+125.0%) |
| Mar 1993 | - | $400.00 K | $400.00 K |
FAQ
- What is Theriva Biologics annual selling, general & administrative expenses?
- What is the all time high annual SG&A for Theriva Biologics?
- What is Theriva Biologics annual SG&A year-on-year change?
- What is Theriva Biologics quarterly selling, general & administrative expenses?
- What is the all time high quarterly SG&A for Theriva Biologics?
- What is Theriva Biologics quarterly SG&A year-on-year change?
- What is Theriva Biologics TTM selling, general & administrative expenses?
- What is the all time high TTM SG&A for Theriva Biologics?
- What is Theriva Biologics TTM SG&A year-on-year change?
What is Theriva Biologics annual selling, general & administrative expenses?
The current annual SG&A of TOVX is $7.12 M
What is the all time high annual SG&A for Theriva Biologics?
Theriva Biologics all-time high annual selling, general & administrative expenses is $10.14 M
What is Theriva Biologics annual SG&A year-on-year change?
Over the past year, TOVX annual selling, general & administrative expenses has changed by -$2.74 M (-27.77%)
What is Theriva Biologics quarterly selling, general & administrative expenses?
The current quarterly SG&A of TOVX is $2.30 M
What is the all time high quarterly SG&A for Theriva Biologics?
Theriva Biologics all-time high quarterly selling, general & administrative expenses is $4.54 M
What is Theriva Biologics quarterly SG&A year-on-year change?
Over the past year, TOVX quarterly selling, general & administrative expenses has changed by +$2.09 M (+985.85%)
What is Theriva Biologics TTM selling, general & administrative expenses?
The current TTM SG&A of TOVX is -$1.28 B
What is the all time high TTM SG&A for Theriva Biologics?
Theriva Biologics all-time high TTM selling, general & administrative expenses is $11.55 M
What is Theriva Biologics TTM SG&A year-on-year change?
Over the past year, TOVX TTM selling, general & administrative expenses has changed by -$1.29 B (-13764.94%)